Professional Documents
Culture Documents
Pharmacodynamics: BIOL 122 DR Hemant Mehta
Pharmacodynamics: BIOL 122 DR Hemant Mehta
Pharmacodynamics
BIOL 122 Dr Hemant Mehta
Week 1 Lec C
Pharmacodynamics
Includes:
- biochemical mechanisms of action (how drugs act on target
cells to alter cellular function)
- Therapeutic effects
1
20/02/2020
2
20/02/2020
3
20/02/2020
4
20/02/2020
Type B reactions
Type B reactions are often caused by immunological and
pharmacogenetic mechanisms.
Type B reactions (only occur in some people) include
unwanted effects due to inherited abnormalities
(ie. idiosyncratic reactions), and immunological processes
(ie. drug allergy).
As they are generally unpredictable and not related to drug
dosage, they are difficult to prevent, resulting in high
morbidity and mortality.
An example of a drug having bizarre (type B) effects is
anaphylaxis due to penicillin.
5
20/02/2020
Anaphylaxis
Angioedema of the face such that the boy is unable to
open his eyes. This reaction was caused by an allergen
exposure.
Source: http//en.wikipedia.org/wiki/Anaphylaxis
Type C reactions
6
20/02/2020
Type D reactions
Type D reactions
Another example is carcinoma of vagina in daughters of
women who took diethylstilbestrol (DES) during pregnancy.
DES is a synthetic oestrogen that was given to some women
during 1940 – 1970 to prevent threatened and recurrent
abortion.
DES caused anatomical abnormalities of uterus, increased
risk of ectopic pregnancy, miscarriage and premature delivery
in the affected daughters.
Type E reactions
7
20/02/2020
8
20/02/2020
Ion channels
Ion channel
receptors
Structure:
Protein pores in the
plasma membrane
9
20/02/2020
Another example:
Neostigmine reacts with acetylcholinesterase to prevent
the inactivation of ACh at the neuro-muscular junction.
10
20/02/2020
Competitive inhibition
• Endogenous substrate and enzyme inhibitor (drug)
compete for the same binding sites. Generally reversible
by increasing the concentration of the substrate.
Non-Competitive inhibition
• Substrate and enzyme inhibitor (drug) compete for
different binding sites. However, binding of a ligand to
one site prevents binding/activation at the other site.
Competitive inhibitors
Normal enzyme action
+ +
Enzyme + substrate enzyme-substrate enzyme + products
complex
Competitive inhibitor
No product
+
Enzyme + inhibitor
Noncompetitive Inhibitors:
+ + No product
11
20/02/2020
Mannitol
Mannitol is used to force urine production in people with
acute (sudden) kidney failure. Increased urine production
helps prevent the kidneys from shutting down, and also
speeds up elimination of certain toxic substances in the
body.
12
20/02/2020
Drug Interactions
13